Skip to main content
SpringerLink
Log in

The EORTC studies: is there an optimal endocrine management for M1 prostatic cancer?

  • Published:
World Journal of Urology Aims and scope Submit manuscript

Summary

The EORTC Genito-Urinary Group has recruited patients into three major phase III trials of the endocrine treatment of advanced prostatic cancer. In terms of time to progression and length of survival, there is no significant difference between any of the effective endocrine treatments that have been studied. As well as these factors, the clinician has to consider treatment toxicity, relief of symptoms and quality of life when he considers the optimal endocrine management for metastatic prostatic cancer. The EORTC studies have not demonstrated that any alternative hormonal therapy is superior to orchidectomy which is not costly and does not produce life-threatening complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Benson RC, Gill GM, Cummings KB (1983) Randomised double blind crossover trial of Diethyl Stilboestrol (DES) and Estramustine Phosphate (ENCYT). The stage D Prostatic Cancer Seminar in Oncology, vol 10, Suppl 3, p 43–45

  2. Bracci U (1977) Our present procedures in the treatment of prostatic cancer. In: Bracci U, Silveria FD Hormonal Therapy of Prostatic Cancer. Cohese, Palermo.

    Google Scholar 

  3. Byar DP (1980) Review of the Veterans' Administrative Studies of Cancer of the Prostate: The new results concerning treatment of Stage I and II tumours. In: Pavone-Macaluso M, Smith PH, Edsmyr S (eds) Bladder Tumours and other topics in Urological Oncology. Plenum Press, New York London, p 471–492

    Google Scholar 

  4. Huggins C, Hodges CV (1941) Studies of Prostatic Cancer. Effect of Castration, Estrogen and Androgen Injection on Serum Phosphatase in Metastatic Carcinoma of the Prostate. Cancer Res 1:293–297

    Google Scholar 

  5. Labrie F, Dupont A, Belanger A (1985) Complete androgen blockade for the treatment of prostatic cancer. In: De Vita VT, Helman S, Rosenberg SA (eds) Important Advances in Oncology. Lippincott Comp, Philadelphia

    Google Scholar 

  6. Pannuti F, Di Marco AR, Martoni A, Fruet F, Strocchi E, Burroni P, Rossi AP, Cricca A (1980) Medroxyprogesterone Acetate in the treatment of metastatic breast cancer: 7 years' experience. In: Iacobelli S, De Marco A (eds) Role of Medroxyprogesterone in endocrine-related tumours. Raven Press, New York, pp 73–92

    Google Scholar 

  7. Pavone-Macaluso M, De Voogt HJ, Viggiano G, Barasolo B, Lardennoi B, De Pauw M, Sylvester R and the members of the Urological EORTC Group (1986) Comparison of Diethyl Stilboestrol and Cyproterone Acetate and Medroxyprogesterone Acetate in the treatment of advanced prostatic cancer: Final analysis of a Phase III Trial of the EORTC Urological Group. J Urol (in press)

  8. Randall A (1942). Eight year results of Castration for Cancer of the Prostate. J Urol 48:706–709

    Google Scholar 

  9. Smith PH, Suciu S, Robinson MRG, Richards B, Bastable JRG, Glashan RW, Bouffioux C, Lardennois B, Williams RE, De Pauw M, Sylvester R (1986) A Comparison of the Effect of Diethyl Stilboestrol with Low-dose Estramustine Phosphate in the Treatment of Advanced Prostatic Cancer: A Phase III Trial of the EORTC Urological Group. J Urol (in press)

  10. Veterans' Administrative Co-operative Urological Research Group (1967). Treatment and Survival of Patients with Cancer of the Prostate. Surg Gynecol Obstet 124:1011–1017

    Google Scholar 

  11. de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S and the members of the European Organisation for the Research and the Treatment of Cancer Urological Group. Cardiovascular side-effects of Diethyl Stilboestrol, Cyproterone Acetate, Medroxyprogesterone Acetate and Estramustine Phosphate used for the treatment of advanced prostatic cancer: Results of the European Organisation for the Research and Treatment of Cancer. Trial 30761 and 30762. J Urol 135:303–307

  12. White JW (1895) The results of double-castration hypertrophy of the prostate. Ann Surg 22:1–80

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pontefract General Infirmary, Friarwood Lane, WF8 1PL, Pontefract, West Yorks

    M. R. G. Robinson

  2. St. James's University Hospital, Leeds, U.K.

    J. Hetherington

Authors
  1. M. R. G. Robinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Hetherington
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robinson, M.R.G., Hetherington, J. The EORTC studies: is there an optimal endocrine management for M1 prostatic cancer?. World J Urol 4, 171–175 (1986). https://doi.org/10.1007/BF00327015

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00327015

Keywords

Search

Navigation